Heartflow Inc

HTFL

Market cap $2.25B

Acquired 312,234 shares of HeartFlow, estimated at ~$10.51 million based on quarterly average price Post-trade position: 312,234 shares, valued at $10.51 million as of 2025-09-30 New position places HeartFlow outside the fund's top five holdings by reported value

MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today reported financial results for the three months ended September 30, 2025.

The market has recently absorbed a surge of activity around AI infrastructure buildouts. NVIDIA CEO Jensen Huang proclaimed in September that global AI infrastructure spending could total $3 trillion to $5 trillion by 2030. As we have written before, technology spending today accounts for just 5% of global GDP.

NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025. The new data add to the robust and growing body of evidence supporting AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging* — the most clinically validated framework for actionable CAD care.

MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic value of Heartflow Plaque Analysis at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7-10 in New Orleans.

MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025.

PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning NAVIGATE-PCI registry to enroll approximately 2,500 patients across approximately 30 sites to evaluate the impact of CT-guided PCI planning in real-world practice MOUNTAIN VIEW, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today introduced Heartflow PCI Navigator, the newest addition to the Heartflow One platform.

Heartflow secures FDA clearance and Cigna coverage for its Next Gen Plaque Analysis, boosting accuracy and nationwide access.

Just after market close on Tuesday, specialized medical device company HeartFlow (HTFL 14.13%) was the very picture of health, as far as its stock was concerned. The company's shares saw a robust 14% boost in price, thanks largely to a nod from one of the world's top health regulators.

AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide